Abstract
Dasatinib is a multikinase inhibitor active against several tyrosine kinases including ABL, KIT, Lyn and Btk. Apart from its known antileukemic activity, the drug produces several side effects including edemas and pleural effusions, which are supposedly triggered by activated immune cells. Effusion formation can be treated effectively by glucocorticosteroids. We have recently shown that low concentrations of dasatinib (<0.1 µM) promote IgE-dependent secretion of histamine in basophils, especially in allergic individuals. In the current study, we asked whether glucocorticosteroids inhibit dasatinib-induced activation of basophils. Basophils were preincubated with dexamethasone, prednisolone and hydrocortisone for 24 h, and were then exposed to an anti-IgE antibody (normal basophils) or the allergens Bet v 1 and Phl p 5 (allergic patients) with or without low concentrations of dasatinib (0.025 µM). After incubation, basophils were examined for histamine release and expression of CD63 and CD203c. All three glucocorticosteroids were found to counteract IgE-dependent and dasatinib-enhanced histamine release in basophils in nonallergic and allergic individuals. In addition, glucocorticosteroids were found to inhibit anti-IgE-induced ...Continue Reading
References
Sep 1, 1991·The Journal of Allergy and Clinical Immunology·E F KnolD Roos
Jul 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·P ValentP Bettelheim
Jul 30, 1981·Nature·R P SchleimerE Gillespie
Nov 26, 1999·The Journal of Investigative Dermatology·S HeissR Valenta
Nov 15, 2000·Biochemical Pharmacology·D MacGlashanS Lavens-Phillips
Jul 12, 2002·The Journal of Allergy and Clinical Immunology·Alexander W HauswirthPeter Valent
Mar 20, 2004·International Archives of Allergy and Immunology·Hans-Jörg BühringPeter Valent
Jun 3, 2004·The Journal of Experimental Medicine·Sandra OdomJuan Rivera
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Dec 24, 2004·Journal of Medicinal Chemistry·Louis J LombardoRobert M Borzilleri
Feb 16, 2005·Expert Opinion on Investigational Drugs·Sheila A Doggrell
Apr 29, 2005·Leukemia·C Gambacorti-PasseriniL Scapozza
Aug 18, 2005·Blood·Shinya KimuraTaira Maekawa
Nov 8, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Wenbin XiaoToshiaki Kawakami
Jan 7, 2006·Cancer Research·Marcus M SchittenhelmMichael C Heinrich
Jan 26, 2006·Blood·Neil P ShahCem Akin
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Jul 15, 2006·Leukemia & Lymphoma·F RadaelliG Lambertenghi-Deliliers
Feb 24, 2007·Blood·Hagop KantarjianNeil Shah
Aug 28, 2007·Blood·Uwe RixGiulio Superti-Furga
Aug 28, 2007·Nature Biotechnology·Marcus BantscheffGerard Drewes
Sep 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alfonso Quintás-CardamaJorge Cortes
Nov 21, 2007·Haematologica·Karoline V GleixnerPeter Valent
Jan 9, 2008·Blood·Michael KneidingerPeter Valent
Mar 12, 2008·British Journal of Haematology·Hugues de LavalladeDavid Marin
Apr 19, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lisa J ChristopherRamaswamy A Iyer
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil P ShahAndreas Hochhaus
Sep 12, 2009·European Journal of Clinical Investigation·C SillaberP Valent
Jul 17, 2010·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·D MacGlashan
Oct 12, 2010·Haematologica·Maria-Theresa KrauthPeter Valent